Evidence of mumps infection among children in the Democratic Republic of Congo

Pediatric Infectious Disease Journal

Volumn 36, Issue 5, 2016, Pages 462-466

  Doshi, Reena H ^a   Alfonso, Vivian H ^a   Hoff, Nicole A ^a   Mukadi, Patrick ^b   Gerber, Sue ^c   Bwaka, Ado ^d   Higgins, Stephen G ^e   Mwamba, Guillaume Ngoie ^f   Okitolonda, Emile ^g   Muyembe, Jean Jacques ^h   Rimoin, Anne W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KINSHASA   (Congo)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d McKing Consulting Corporation   (Congo)

^e OpGen Inc   (United States)

^f Ministry of Health   (Congo)

^g Kinshasa School of Public Health   (Congo)

^h Institut National de Recherche Bio Medicale   (Congo)

Author keywords

Democratic Republic of Congo; Immunization; Mumps; Vaccine preventable diseases

Indexed keywords

ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CHILD; CHILDHOOD DISEASE; DEMOCRATIC REPUBLIC CONGO; DRIED BLOOD SPOT TESTING; FEMALE; HOUSEHOLD; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUMPS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; SOCIAL STATUS; ADOLESCENT; ADULT; ANIMAL; BLOOD; IMMUNOLOGY; MIDDLE AGED; MUMPS VIRUS; YOUNG ADULT;

VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DEMOCRATIC REPUBLIC OF THE CONGO; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MUMPS; MUMPS VIRUS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 85007158138     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001483     Document Type: Article

References (33)

1. Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J. 2001;20:380–391.
2. World Health Organization. Mumps virus vaccines. WER. 2007;82:50.
3. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77:3–14.
4. Hviid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008;371:932–944.
5. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358:1580–1589.
6. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ. 2005;330:1132–1135.
7. Janaszek-Seydlitz W, Bucholc B, Gorska P, et al. Mumps in Poland since 1990 to 2003; epidemiology and antibody prevalence. Vaccine. 2005;23:2711–2716.
8. Morgan-Capner P, Wright J, Miller CL, et al. Surveillance of antibody to measles, mumps, and rubella by age. BMJ. 1988;297:770–772.
9. Ruiz-Gomez J, Espinosa-Larios EL. Seroepidemiology of rubella, measles and mumps in the Republic of Mexico. IV. Rubella. Salud Publica Mex. 1978;20:29–33.
10. Wagenvoort JH, Harmsen M, Boutahar-Trouw BJ, et al. Epidemiology of mumps in the Netherlands. J Hyg (Lond). 1980;85:313–326.
11. Al-Mazrou YY, Khalil MK, Tischer A, et al. Serosurvey of measles, mumps and rubella antibodies in Saudi children. Saudi Med J. 2005;26:1551–1554.
12. McIntyre JP, Keen GA. Laboratory surveillance of viral meningitis by examination of cerebrospinal fluid in Cape Town, 1981-9. Epidemiol Infect. 1993;111:357–371.
13. World Health Organization. Reported immunization schedules by vaccine. 2016.
14. World Health Organization. Vaccine introduction guidelines. Adding a Vaccine to a National Immunization Programme: Decision and Implementation. Geneva: World Health Organization; 2005.
15. Minister of Plan, Minister of Health, International I. Demographic and Health Survey: Democratic Republic of Congo 2013–14. Supplementational Vaccine-Preventable Diseases. Rockville, MD: ICF International; 2014.
16. ICF International. Sampling and Household Listing Manual. Calverton, MD: ICF International; 2012.
17. Mercader S, Featherstone D, Bellini WJ. Comparison of available methods to elute serum from dried blood spot samples for measles serology. J Virol Methods. 2006;137:140–149.
18. Higgins SG. Validations of Dynex multiplexed serology panel for Measles, Mumps, Rubella, Varicella Zoster Virus and Tetanus. 2016.
19. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982;136:362–364.
20. World Health Organization, United Nations Children’s Emergency Fund, World Bank. State of the World’s Vaccines and Immunization. 3rd ed. Geneva: World Health Organization; 2009.
21. Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis. 2004;189(suppl 1):S131–S145.
22. United Nations Children’s Emergency Fund. Vaccine price data. 2016.
23. Paulo F., Mohammed D. Barriers to immunization coverage in DRC: an analysis of the GAVI-Alliance cash-based support. Ann Trop Med PH. 2013;6:401–407.
24. Centers for Disease Control and Prevention. Progress toward measles control—African region, 2001–2008. MMWR Morb Mortal Wkly Rep. 2009;58:1036–1041.
25. Minetti A, Bopp C, Fermon F, et al. Measles outbreak response immunization is context-specific: insight from the recent experience of Medecins Sans Frontieres. PLoS Med. 2013;10:e1001544.
26. Centers for Disease Control and Prevention. Measles outbreaks and progress toward measles preelimination—African region, 2009–2010. MMWR Morb Mortal Wkly Rep. 2011;60:374–378.
27. Shibeshi ME, Masresha BG, Smit SB, et al. Measles resurgence in southern Africa: challenges to measles elimination. Vaccine. 2014;32:1798–1807.
28. Ministry of Health, Programme Elargi de Vaccination. Plan Stratégique d’élimination de la Rougeole 2012–2020. 2012. Report No.
29. Doshi RH, Shidi C, Mulumba A, et al. The effect of immunization on measles incidence in the Democratic Republic of Congo: results from a model of surveillance data. Vaccine. 2015;33:6786–6792.
30. World Health Organization. WHO vaccine-preventable diseases: monitoring system: 2015 global summary. 2016
31. World Health Organization, Centers for Disease Control and Prevention. Technical guidelines for integrated disease surveillance and response in the African region, Brazzaville, Republic of Congo and Atlanta, USA. 2010:1–398.
32. Cameron NA. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa? Vaccine. 2012;30(suppl 3):C58–C60.
33. World Health Organization. Global Measles and Rubella Strategic Plan: 2012–2020. Geneva: 2012.